Alterity Therapeutics Limited (ATHE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Alterity Therapeutics Limited (ATHE) closed at USD 2.81 on 2026-10-14, a change of -41 % over the past year, with a market capitalization of USD 49.53M.

Alterity Therapeutics Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alterity Therapeutics Limited key figures

Previous close

USD 2.81 (2026-10-14)

1-year change

-41 %

Market cap

USD 49.53M

Enterprise value

USD 12.4M

P/E ratio (trailing)

-3.02

P/E ratio (forward)

-2.84

EPS (trailing)

-0.90

EPS (forward)

-0.96

PEG ratio

n/a

Price to book

1.66

Revenue growth

-79 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.68

Employees

11

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alterity Therapeutics Limited

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alterity Therapeutics Limited and compare it with other stocks.